CCS
NPTN

Crosspoint Capital Strategies’s NEOPHOTONICS CORP NPTN Stock Holding History

Crosspoint Capital Strategies’s Portfolio NPTN Stock Details NPTN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,700
Closed -$13K – 653
2014
Q1 		$13K Buy
+1,700
New +$12.7K 0.01% 443

Other funds holding NPTN

AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
ARM
Adirondack Research & Management Guilderland, New York $82.2M AUM 63.78% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
QAM
Quentec Asset Management New York $634M AUM 22.87% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Crosspoint Capital Strategies's NPTN Position: Q2 2014 in Review

Crosspoint Capital Strategies sold out of NEOPHOTONICS CORP (NPTN) in Q2 2014, closing a stake of 1,700 shares — an estimated $13K sold.

Crosspoint Capital Strategies first reported a position in NPTN in Q1 2014 and held it in 1 quarter. The position peaked at $13K in Q1 2014. 60 funds tracked by Wall St. Rank hold NPTN as of Q2 2014.

  • Crosspoint Capital Strategies reported no remaining NEOPHOTONICS CORP position as of Q2 2014 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 1,700 NEOPHOTONICS CORP shares in Q2 2014, an estimated $13K.
  • Crosspoint Capital Strategies first reported a position in NEOPHOTONICS CORP in Q1 2014 and held it in 1 quarter.
  • Crosspoint Capital Strategies's NEOPHOTONICS CORP position peaked at $13K in Q1 2014.
  • 60 funds tracked by Wall St. Rank held NEOPHOTONICS CORP as of Q2 2014.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2014, filed 29 Jul 2014.